Cholangiocarcinoma: A Comprehensive Review and Update Guideline

Authors

Kadek Nandita Nugraha , Baiq Inna Dwi Hardyningrat , Devi Chandra Kirana , Najla Aulia Yahya , Salsabila Dinda Nuril Ishlahi , Shofia Kadarisma , Fathul Djannah

DOI:

10.29303/jppipa.v10i10.8419

Published:

2024-10-25

Issue:

Vol. 10 No. 10 (2024): October

Keywords:

Cholangiocarcinoma, Guideline cholangiocarcinoma, Management cholangiocarcinoma

Review

Downloads

How to Cite

Nugraha, K. N., Hardyningrat, B. I. D., Kirana, D. C., Yahya, N. A., Ishlahi, S. D. N., Kadarisma, S., & Djannah, F. (2024). Cholangiocarcinoma: A Comprehensive Review and Update Guideline. Jurnal Penelitian Pendidikan IPA, 10(10), 693–703. https://doi.org/10.29303/jppipa.v10i10.8419
Crossref
Scopus
Google Scholar
Europe PMC

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Abstract

Cholangiocarcinoma is a rare cancer of the gastrointestinal system. However, the prognosis for people with this disease has not improved in the last decade. CCA has a poor prognosis because most cases are diagnosed at an advanced stage and the availability of treatment options is limited.  This literature review aims to provide information regarding the current understanding and guidelines for cholangiocarcinoma. In this literature review, we searched the National Center for Biotechnology Information (NCBI) and Google Scholar using the search keywords "Cholangiocarcinoma", "cholangiocarcinoma management", "cholangiocarcinoma guidelines" taken ScienceDirect, Researchgate, National Comprehensive Cancer Network, and PubMed published in the last 10 years. From various databases, the literature used and according to the selection criteria amounted to 50 articles In the latest articles and the Cancers NCCN Guidelines for Biliary Tract Cancer in 2023, CCA treatment is carried out based on the patient's profile. Targeted therapy is an additional treatment option today by targeting the molecular profile involved in the pathogenesis of CCA. The diagnosis of cholangiocarcinoma is made through histology, radiography, and laboratory examination. Based on the Cancers NCCN Guidelines for Biliary Tract Cancer in 2023, the treatment carried out consists of determining cancer staging, surgery, radiation therapy, and systemic therapy.

References

Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., & Vogel, A. (2020). Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. The Lancet Oncology, 21(5), 671–684. https://doi.org/10.1016/S1470-2045(20)30109-1

Aslam, M. S., Naveed, S., Ahmed, A., Abbas, Z., Gull, I., & Athar, M. A. (2014). Side Effects of Chemotherapy in Cancer Patients and Evaluation of Patients Opinion about Starvation Based Differential Chemotherapy. Journal of Cancer Therapy, 05(08), 817–822. https://doi.org/10.4236/jct.2014.58089

Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., & Gores, G. J. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology, 17(9), 557–588. https://doi.org/10.1038/s41575-020-0310-z

Barros, A. Z. D. A., Fonseca, G. M., Kruger, J. A. P., Coelho, F. F., & Herman, P. (2022). Liver resection for hepatocellular carcinoma beyond the BCLC: Are multinodular disease, portal hypertension, and portal system invasion real contraindications? Journal of Gastrointestinal Oncology, 13(6), 3123–3134. https://doi.org/10.21037/jgo-22-833

Benson, M. I. D. ’Angelic., Abrams, T., Abbott, D. E., Ahmed, A., & Anaya, D. A. (2023). NCCN Guidelines for Patients Biliary Tract Cancers. Retrieved from https://www.nccn.org/guidelines/

Cai, H., Kong, W.-T., Chen, C.-B., Shi, G.-M., Huang, C., Shen, Y.-H., & Sun, H.-C. (2015). Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: A meta-analysis of observational studies. BMC Cancer, 15(1), 831. https://doi.org/10.1186/s12885-015-1870-0

Cillo, U., Fondevila, C., Donadon, M., Gringeri, E., Mocchegiani, F., Schlitt, H. J., & Groot Koerkamp, B. (2019). Surgery for cholangiocarcinoma. Liver International, 39(S1), 143–155. https://doi.org/10.1111/liv.14089

Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Journal of Hepatology, 72(1), 95–103. https://doi.org/10.1016/j.jhep.2019.09.007

Du, J., Lv, X., Zhang, Z., Huang, Z., & Zhang, E. (2023). Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. Frontiers in Immunology, 14, 1142690. https://doi.org/10.3389/fimmu.2023.1142690

Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., & Massironi, S. (2022). Clinical treatment of cholangiocarcinoma: An updated comprehensive review. Annals of Hepatology, 27(5), 100737. https://doi.org/10.1016/j.aohep.2022.100737

Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz, M., & Lamarca, A. (2019). Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver International, 1, 98–107. https://doi.org/10.1111/liv.14086

Geramizadeh, B. (2020). Precursor Lesions of Cholangiocarcinoma: A Clinicopathologic Review. Clinical Pathology, 13, 2632010 2092504. https://doi.org/10.1177/2632010X20925045

Giovannoni, R., & Villanueva, A. (2016). Circulating tumor cells and cholangiocarcinoma. Hepatology, 63(1), 23–25. https://doi.org/10.1002/hep.28152

Guedj, N. (2022). Pathology of Cholangiocarcinomas. Current Oncology, 30(1), 370–380. https://doi.org/10.3390/curroncol30010030

Gyawali, S., Adhikari, G., Shrestha, S., Pradhan, S., & Bhandari, R. S. (2021). Concomitant hilar cholangiocarcinoma with choledochal cyst and cholelithiasis in an asymptomatic patient: A case report. International Journal of Surgery Case Reports, 84, 106094. https://doi.org/10.1016/j.ijscr.2021.106094

Huang, Y., You, L., Xie, W., Ning, L., & Lang, J. (2017). Smoking and risk of cholangiocarcinoma: A systematic review and meta-analysis. Oncotarget, 8(59), 100570–100581. https://doi.org/10.18632/oncotarget.20141

Ioffe, D., Phull, P., & Dotan, E. (2021). Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Management and Research, 13, 8085–8098. https://doi.org/10.2147/CMAR.S276104

Jaklitsch, M., & Petrowsky, H. (2019). The power to predict with biomarkers: Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) serum markers in intrahepatic cholangiocarcinoma. Translational Gastroenterology and Hepatology, 4, 23–23. https://doi.org/10.21037/tgh.2019.03.06

Jakubowski, C. D., & Azad, N. S. (2020). Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma. Chinese Clinical Oncology, 9(1), 2–2. https://doi.org/10.21037/cco.2019.12.10

Jiang, T., Lyu, S.-C., Zhou, L., Wang, J., Li, H., He, Q., & Lang, R. (2021). Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma. World Journal of Gastrointestinal Surgery, 13(9), 1025–1038. https://doi.org/10.4240/wjgs.v13.i9.1025

Kelley, R. K., Bridgewater, J., Gores, G. J., & Zhu, A. X. (2020). Systemic therapies for intrahepatic cholangiocarcinoma. Journal of Hepatology, 72(2), 353–363. https://doi.org/10.1016/j.jhep.2019.10.009

Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., & Zhao, H. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 401(10391), 1853–1865. https://doi.org/10.1016/S0140-6736(23)00727-4

Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., & Carpino, G. (2019). Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver International, 39(S1), 7–18. https://doi.org/10.1111/liv.14093

Khan, S. A., Tavolari, S., & Brandi, G. (2019). Cholangiocarcinoma: Epidemiology and risk factors. Liver International, 39(S1), 19–31. https://doi.org/10.1111/liv.14095

Krishna, S., Mishra, A., Ravina, M., Kashyap, Y., Bansal, H., & Dasgupta, S. (2022). Primary biliary tuberculosis masquerading cholangiocarcinoma in 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Indian Journal of Nuclear Medicine, 37(3), 265. https://doi.org/10.4103/ijnm.ijnm_204_21

Labib, P. L., Goodchild, G., & Pereira, S. P. (2019). Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer, 19(1), 185. https://doi.org/10.1186/s12885-019-5391-0

Lee, J. J., Schindera, S. T., Jang, H.-J., Fung, S., & Kim, T. K. (2017). Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis. Abdominal Radiology, 42(12), 2898–2908. https://doi.org/10.1007/s00261-017-1328-8

Li, J., Han, T., Xu, L., & Luan, X. (2015). Diabetes mellitus and the risk of cholangiocarcinoma: An updated meta-analysis. Gastroenterology Review, 2, 108–117. https://doi.org/10.5114/pg.2015.49004

Li, S., Deng, M., Wang, Q., Mei, J., Zou, J., Lin, W., & Guo, R. (2022). Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma. Journal of Oncology, 1–7. https://doi.org/10.1155/2022/2724476

Liu, S., Fan, S., Wang, Y., Chen, R., Wang, Z., Zhang, Y., & Li, X. (2023). ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma. BMC Cancer, 23(1), 444. https://doi.org/10.1186/s12885-023-10903-5

Navas, M.-C., Glaser, S., Dhruv, H., Celinski, S., Alpini, G., & Meng, F. (2019). Hepatitis C Virus Infection and Cholangiocarcinoma. The American Journal of Pathology, 189(6), 1122–1132. https://doi.org/10.1016/j.ajpath.2019.01.018

Paiella, S., Pastena, M., Pollini, T., Zancan, G., Ciprani, D., Marchi, G., & Salvia, R. (2017). Pancreaticoduodenectomy in patients ≥ 75 years of age: Are there any differences with other age ranges in oncological and surgical outcomes? Results from a tertiary referral center. World Journal of Gastroenterology, 23(17), 3077. https://doi.org/10.3748/wjg.v23.i17.3077

Pang, L., Hu, S., Dai, W., Wu, S., & Kong, J. (2021). Dilemma of the differential diagnosis of hilar cholangiocarcinoma and benign diseases: A single-center retrospective study. Carcinogenesis, 42(3), 442–447. https://doi.org/10.1093/carcin/bgaa125

Patel, V., Musa, R., Patel, N., & Patel, S. (2022). Role of MRCP to determine the etiological spectrum, level and degree of biliary obstruction in obstructive jaundice. Journal of Family Medicine and Primary Care, 11(7), 3436. https://doi.org/10.4103/jfmpc.jfmpc_2362_21

Proskuriakova, E., & Khedr, A. (2022). Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review. Cureus. https://doi.org/10.7759/cureus.26233

Qiang, Z., Zhang, W., Jin, S., Dai, K., He, Y., Tao, L., & Yu, H. (2021). Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study. Annals of Hepatology, 20, 100242. https://doi.org/10.1016/j.aohep.2020.07.010

Qurashi, M., Vithayathil, M., & Khan, S. A. (2023). Epidemiology of cholangiocarcinoma. European Journal of Surgical Oncology, 10. https://doi.org/10.1016/j.ejso.2023.107064

Rodrigues, P. M., Vogel, A., Arrese, M., Balderramo, D. C., Valle, J. W., & Banales, J. M. (2021). Next-Generation Biomarkers for Cholangiocarcinoma. Cancers, 13(13), 3222. https://doi.org/10.3390/cancers13133222

Sarcognato, S., Sacchi, D., Fassan, M., Fabris, L., Cadamuro, M., Zanus, G., & Guido, M. (2021). Cholangiocarcinoma. Pathologica, 113(3), 158–169. https://doi.org/10.32074/1591-951X-252

Shin, D. W., Moon, S.-H., & Kim, J. H. (2023). Diagnosis of Cholangiocarcinoma. Diagnostics, 13(2), 233. https://doi.org/10.3390/diagnostics13020233

Surya, H., Abdullah, M., Nelwan, E. J., Syam, A. F., Prasetya, I. B., Stefanus, B., & Shatri, H. (2023). Current Updates on Diagnosis and Management of Cholangiocarcinoma: From Surgery to Targeted Therapy. Acta Med Indones, 55(3). Retrieved from https://europepmc.org/article/med/37915146

Testa, U., Pelosi, E., & Castelli, G. (2023). Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin. Technology in Cancer Research & Treatment, 22. https://doi.org/10.1177/15330338221128689

Turati, F., Bertuccio, P., Negri, E., & Vecchia, C. (2022). Epidemiology of cholangiocarcinoma. Hepatoma Research, 8, 19. https://doi.org/10.20517/2394-5079.2021.130

Vijgen, S., Terris, B., & Rubbia-Brandt, L. (2017). Pathology of intrahepatic cholangiocarcinoma. HepatoBiliary Surgery and Nutrition, 6(1), 22–34. https://doi.org/10.21037/hbsn.2016.11.04

Vithayathil, M., & Khan, S. A. (2022). Current epidemiology of cholangiocarcinoma in Western countries. Journal of Hepatology, 77(6), 1690–1698. https://doi.org/10.1016/j.jhep.2022.07.022

Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., & Ducreux, M. (2022). Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(2), 127–140. https://doi.org/10.1016/j.annonc.2022.10.506

Vogel, A., Saborowski, A., Wenzel, P., Wege, H., Folprecht, G., Kretzschmar, A., & Kirstein, M. M. (2024). Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): A multicentre, open-label, rand. The Lancet Gastroenterology & Hepatology, 9(8), 734–744. https://doi.org/10.1016/S2468-1253(24)00119-5

Yadlapati, S. (2021). Cholangiocarcinoma surveillance in patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Advanced Research in Gastroenterology & Hepatology, 17(1). https://doi.org/10.19080/ARGH.2021.17.555954

Zhang, H., Han, C., Zheng, X., Zhao, W., Liu, Y., & Ye, X. (2023). Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review. Journal of Cancer Research and Therapeutics, 19(4), 1055–1060. https://doi.org/10.4103/jcrt.jcrt_1697_22

Zhang, X., Zhou, Y., Wu, Z., Peng, W., Li, C., Yan, L., & Wen, T. (2021). Double-Negative α-Fetoprotein and Carbohydrate Antigen 19-9 Predict a Good Prognosis in Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Clinical and Translational Gastroenterology, 12(11), 425. https://doi.org/10.14309/ctg.0000000000000425

Author Biographies

Kadek Nandita Nugraha, Mataram University

Baiq Inna Dwi Hardyningrat, Mataram University

Devi Chandra Kirana, Mataram University

Najla Aulia Yahya, Mataram University

Salsabila Dinda Nuril Ishlahi, Mataram University

Shofia Kadarisma, Mataram University

Fathul Djannah, Mataram University

License

Copyright (c) 2024 Kadek Nandita Nugraha, Baiq Inna Dwi Hardyningrat, Devi Chandra Kirana, Najla Aulia Yahya, Salsabila Dinda Nuril Ishlahi, Shofia Kadarisma, Fathul Djannah

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with Jurnal Penelitian Pendidikan IPA, agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC-BY License). This license allows authors to use all articles, data sets, graphics, and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Jurnal Penelitian Pendidikan IPA.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).